Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Y Jimenez López"'
Autor:
E Perez Cano, Y Jimenez López, CL Muñoz Cid, N Garcia Gomez, R Claramunt García, JF Marin Pozo
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Anti-PD-L1 immunotherapy is used to treat secondline or later non-small cell lung cancer (NSCLC). These monoclonal antibodies are the therapy of choice against NSCLC in routine clinical practice. Aim and objectives To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3c71410b02ee95c63c0d84222393b98
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
Autor:
M Merino Almazan, R Claramunt García, I Caba Porras, Y Jimenez López, MI Sierra Torres, E Perez Cano
Publikováno v:
Section 3: Production and Compounding.
Background and importance Multiple food allergy (MFA), in its severe stage, is a pathology with nutritional and pharmacotherapeutic restrictions. Drug intolerance to available medicines and lack of alternatives can lead to magistral formulations. Aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e80cb592e7cee722b941fdc900db4aea
https://doi.org/10.1136/ejhpharm-2020-eahpconf.72
https://doi.org/10.1136/ejhpharm-2020-eahpconf.72
Autor:
R Claramunt García, A Sánchez Ruiz, Arlene López, E Perez Cano, CL Muñoz Cid, Y Jimenez López, J Jerez Rojas
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance In recent years innovative therapies have been developed for the treatment of hypercholesterolaemia that allow an effective decrease in low density lipoprotein (LDL)-cholesterol (LDL-c). These are alirocumab and evolocumab,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbb10b10e066576334d6b8cceafa3f22
https://doi.org/10.1136/ejhpharm-2020-eahpconf.121
https://doi.org/10.1136/ejhpharm-2020-eahpconf.121
Autor:
R Claramunt García, T Vilchez Medina, Arlene López, N Garcia Gomez, CL Muñoz Cid, E Perez Cano, Y Jimenez López, L Martinez-Dueñas Lopez-Marin
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Medication errors are frequent in the hospital setting, increasing the morbidity and mortality of patients. The pharmacist detects medication errors, preventing the appearance of medication related problems through pharmaceu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cafefdaf532d571a6ca178cf0b29d36d
https://doi.org/10.1136/ejhpharm-2020-eahpconf.268
https://doi.org/10.1136/ejhpharm-2020-eahpconf.268
Autor:
R Claramunt García, N Garcia Gomez, Y Jimenez López, T Vilchez Medina, CL Muñoz Cid, E Perez Cano, L Martinez-Dueñas Lopez-Marin, A López López
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Medication errors at hospital admission are common, increasing morbidity and mortality. The pharmacist can help to prevent the occurrence of medication related problems through medication reconciliation. Aim and objectives T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20a2c63e3dae44dabdd0f537ff1190f6
https://doi.org/10.1136/ejhpharm-2020-eahpconf.292
https://doi.org/10.1136/ejhpharm-2020-eahpconf.292
Autor:
R Claramunt García, E Perez Cano, CL Muñoz Cid, Almudena López-López, Y Jimenez López, M Merino Almazan, J Jerez Rojas, MJ Barbero Hernandez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Psoriasis is a disease that requires long-term treatment. Apremilast is indicated in the treatment of psoriasis in patients who have not responded or have contraindicated or cannot tolerate other treatment systemics. This drug has a lower
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52afd26f76b8b7de7e93b9b304e7a80b
https://doi.org/10.1136/ejhpharm-2019-eahpconf.184
https://doi.org/10.1136/ejhpharm-2019-eahpconf.184
Autor:
R Claramunt García, JF Marin Pozo, I Caba Porras, M Merino Almazan, AM López-López, Y Jimenez López, CL Muñoz Cid, E Perez Cano
Publikováno v:
Section 3: Production and Compounding.
Background Primary bladder neck obstruction (PBNO) is a failure in which the bladder neck does not open appropriately or completely during voiding. α-Blocker together with anticholinergics are the pharmacological therapy that has shown some benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41ea499b78d81f2ed0403db3bb79a1ce
https://doi.org/10.1136/ejhpharm-2019-eahpconf.140
https://doi.org/10.1136/ejhpharm-2019-eahpconf.140
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.